Johnathan Q. Trinh, MD, et al discuss a novel case of a patient with an aggressive CDKN2A-mutated spiradenocarcinoma who responded to a CDK4/6 inhibitor.
Shristi Upadhyay Banskota, MBBS
Advertisement
Articles by Shristi Upadhyay Banskota, MBBS
Advertisement
Latest Updated Articles
A Rare Case of Metastatic Spiradenocarcinoma With CDKN2A MutationPublished: June 12th 2024 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group
2
What is the Impact of the SHARON Trial on Pancreatic Cancer Research?
3
Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy
4
ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma
5
